Dupuytren’s Contracture and Diabetes

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider regarding any medical condition or treatment.

Key Takeaways

  • Dupuytren's contracture is progressive thickening of the palmar fascia that pulls one or more fingers — usually the ring and little fingers — into permanent flexion at the metacarpophalangeal and proximal interphalangeal joints.
  • It is roughly 1.6 times more common in people with diabetes; diabetic Dupuytren tends to be milder, more bilateral, and slower-progressing than the non-diabetic Northern European form.
  • Diagnosis is clinical — palpable nodules and cords in the palm, with the table-top test (inability to flatten the hand on a table) marking the threshold for considering treatment.
  • Mild disease is observed; moderate disease is treated with percutaneous needle aponeurotomy or collagenase clostridium histolyticum (Xiaflex) injection; severe or recurrent disease is treated with open fasciectomy.
  • Recurrence is the rule rather than the exception — about 50 percent within 5 years for less invasive procedures and 15 to 30 percent for open surgery — so realistic expectations are key.

Dupuytren’s contracture is progressive thickening of the palmar fascia that pulls fingers — usually the ring and little fingers — into permanent flexion. It is about 1.6 times more common in people with diabetes, often more bilateral and less severe than the non-diabetic form. Diagnosis is clinical, with the table-top test marking the threshold for treatment. Options include observation, needle aponeurotomy, collagenase injection (Xiaflex), and open fasciectomy — with recurrence common across all approaches.

What Dupuytren’s Contracture Is

The palmar fascia is a sheet of tough connective tissue that anchors the skin of the palm to the underlying bone and tendons. In Dupuytren disease, abnormal fibroblasts called myofibroblasts proliferate within the fascia and form nodules, then cords. The cords contract along the line of the digital tendons, slowly pulling the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints into flexion. The ring and little fingers are most affected, the middle finger less so, and the index and thumb less still. The disease can affect the foot (Ledderhose disease) and penis (Peyronie disease) by the same biology.

Dupuytren is most common in people of Northern European descent — “Viking disease” — but occurs worldwide. In diabetic populations the prevalence is higher and the disease often presents differently.

Why It Is More Common in Diabetes

  • Increased collagen cross-linking from advanced glycation end-products (AGEs)
  • Up-regulation of TGF-beta and pro-fibrotic cytokines
  • Microvascular changes promoting myofibroblast activity
  • Long-duration diabetes is the strongest risk factor
  • Both type 1 and type 2 diabetes raise risk
  • Higher A1C correlates with greater prevalence

Diabetic Versus Non-Diabetic Dupuytren

Feature Diabetic Dupuytren Classic Northern European
Severity Often milder Frequently more severe
Bilaterality More commonly bilateral Often unilateral first
Fingers affected Middle and ring more common Ring and little more typical
Progression Slower Faster, especially with diathesis
Family history Less prominent Strong genetic clustering
Coexisting conditions Frozen shoulder, trigger finger, carpal tunnel Often isolated to hand

Risk Factors

  • Diabetes (type 1 or type 2)
  • Older age — typically 50 plus
  • Male sex (3 to 4 times more common, gap narrows with age)
  • Northern European ancestry
  • Family history
  • Alcohol use
  • Smoking
  • Manual work and previous hand trauma (debated)
  • Epilepsy and anticonvulsant use (older literature)

Symptoms and Stages

  • Painless nodules in the palm near the base of the ring or little finger
  • Skin pits or dimples over the nodules
  • Palpable cords extending from palm toward the finger
  • Gradual MCP joint flexion contracture
  • Later PIP joint involvement
  • Difficulty washing the face, shaking hands, wearing gloves
  • Functional impact often progressive over years

Diagnosis

Clinical Examination

  • Inspect palm for nodules, pits, and cords
  • Palpate to distinguish skin-tethered cords from tendons
  • Measure MCP and PIP joint contractures with goniometer
  • Table-top test (Hueston) — patient places palm flat; inability to flatten is positive
  • Document any Garrod nodules over PIP joint dorsum (diathesis sign)
  • Check for Ledderhose plantar nodules and Peyronie

Imaging

  • Usually not needed
  • Ultrasound rarely used for diagnostic clarification
  • MRI almost never indicated

Differential Diagnosis

  • Stenosing tenosynovitis (trigger finger)
  • Camptodactyly
  • Ulnar nerve palsy with intrinsic minus posture
  • Diabetic stiff hand syndrome / cheiroarthropathy
  • Tendon nodule
  • Inclusion cyst

Treatment

Observation

  • Most early disease without functional impact
  • Stretching exercises and patient education
  • Monitor for progression every 6 to 12 months

Percutaneous Needle Aponeurotomy

  • In-office procedure under local anesthesia
  • Needle used to weaken cord, then manual extension breaks it
  • Rapid recovery, modest cost
  • Best for MCP contractures and cord-dominant disease
  • Higher recurrence than open surgery

Collagenase Clostridium Histolyticum (Xiaflex)

  • Enzyme injected into cord; manipulation 24 to 72 hours later
  • Office-based
  • FDA-approved for MCP and PIP contractures
  • Recurrence rates similar to needle aponeurotomy
  • Skin tears and bruising common

Open Fasciectomy

  • Surgical removal of diseased fascia
  • Best for severe, recurrent, or PIP-dominant disease
  • Longer recovery (weeks to months)
  • Hand therapy after surgery is essential
  • Lowest recurrence rates

Dermofasciectomy

  • Removal of involved skin and fascia, with skin graft
  • Reserved for very aggressive or recurrent disease
  • Lower recurrence rate within grafted area

Radiation Therapy

  • Low-dose external beam in early nodular disease
  • Aims to halt progression rather than reverse established contracture
  • European centers more familiar with use

Comparing Outcomes

Treatment Recurrence at 5 Years Recovery Time Best For
Needle aponeurotomy About 50 percent Days MCP contractures, mild-moderate
Collagenase injection About 50 percent 1 to 2 weeks MCP and some PIP
Open fasciectomy 15 to 30 percent 6 to 12 weeks Severe, recurrent, or PIP-dominant
Dermofasciectomy Lowest 8 to 12 weeks Aggressive disease, skin involvement

Coexisting Hand Conditions in Diabetes

Condition Description Prevalence in Diabetes
Stiff hand syndrome (cheiroarthropathy) Limited joint mobility, prayer sign positive 30 to 50 percent in long-duration T1D
Trigger finger Stenosing flexor tenosynovitis 5 to 10 percent vs 2 percent general
Carpal tunnel syndrome Median nerve compression at wrist 14 to 30 percent
Frozen shoulder Adhesive capsulitis 10 to 20 percent

Glycemic Control and Procedure Planning

  • Optimize A1C before elective surgery — see our A1C levels guide
  • Watch for delayed wound healing
  • Consider infection risk in immunocompromised states
  • Continue hand therapy regardless of intervention type

Prevention and Long-Term Management

  • Tight glycemic control may slow progression
  • Daily hand stretching
  • Avoid prolonged repetitive trauma where possible
  • Address coexisting hand and shoulder issues such as frozen shoulder
  • Smoking and heavy alcohol reduction
  • Regular hand exam during annual diabetes review — see our complications and related conditions hub for the wider picture

The Bottom Line

Dupuytren’s contracture is progressive thickening of the palmar fascia causing finger flexion deformity, and is more common in people with diabetes. Diabetic Dupuytren tends to be milder, more bilateral, and slower than the classic Northern European form, though disabling cases still occur. Diagnosis is clinical, with the table-top test marking the threshold for intervention. Mild disease is observed; moderate disease is treated with needle aponeurotomy or collagenase injection; severe or recurrent disease is treated with open fasciectomy. Recurrence is common across treatments, so realistic expectations matter. Talk to your doctor at the first sign of palm nodules or finger stiffness, especially if it interferes with daily tasks.

Frequently Asked Questions

What does Dupuytren's contracture look like?

Early disease shows small, firm nodules in the palm, often near the base of the ring or little finger. Over months to years, cord-like thickening forms along the path of a tendon, and the finger begins to bend toward the palm. People notice they cannot fully open the hand to put on gloves, shake hands, or lay the palm flat on a table. Skin pits and dimples often appear over the nodules.

Is Dupuytren's contracture painful?

Most Dupuytren nodules and cords are painless. Some early nodules feel tender or stiff when pressed, and people may notice an ache after manual work. Pain is more often a feature of trigger finger or carpal tunnel syndrome — conditions that frequently coexist with Dupuytren in diabetes. New severe pain in a Dupuytren hand warrants evaluation for another cause.

When should Dupuytren's contracture be treated?

A common rule is to consider intervention when the table-top test becomes positive — the person cannot lay the palm flat on a table — usually corresponding to about 30 degrees of fixed flexion at the metacarpophalangeal joint. PIP joint contractures of any degree are often treated sooner because they are harder to correct once established. Mild or non-progressive disease is usually observed.

Does treating Dupuytren cure it?

No. Current treatments — needling, collagenase injection, fasciectomy — release the contracted tissue but do not change the underlying biology. Recurrence rates are roughly 50 percent within 5 years for needling and collagenase, and 15 to 30 percent for open fasciectomy. Treatment can be repeated, and many people achieve good long-term function despite recurrence. Goals are functional improvement, not permanent cure.

Sources

  1. American Academy of Orthopaedic Surgeons. Dupuytren contracture practice guideline.
  2. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care 47(Suppl 1).